Latest news

• NICE to look again at Pfizer’s Besponsa after appeal

  Pfizer argued that Besponsa treatment more than doubled complete remission rates and made it more likely that patients could go on to receive a stem cell transplant. ... UK practice, however, would largely consist of using [Besponsa] as a step to enable

• FDA clears Pfizer's leukaemia drug Besponsa

  Pfizer has bagged US approval for Besponsa - its treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) - two months after it got the go-ahead in ... Besponsa has been approved with a boxed warning for

• NICE set to reject Pfizer's leukaemia drug Besponsa

  The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa (inotuzumab ozogamicin). ... For its part Pfizer pointed to the INO-VATE trial, which showed Besponsa more than doubled complete

• NICE rejects Pfizer's antibody drug for leukaemia

  The National Institute for Health and Care Excellence (NICE) has turned down Pfizer’s leukaemia drug Besponsa in draft guidance. ... Pfizer estimates that 117 patients would be eligible for treatment with Besponsa in its first year if it were

• CHMP backs two rare disease therapies at April meeting

  In other news from the CHMP meeting, Pfizer picked up a positive opinion for Besponsa (inotuzumab ozogamicin) as a single-agent treatment for adults with relapsed or refractory CD22-positive